Federated Hermes’s Kite Pharma, Inc. KITE Stock Holding History

Federated Hermes’s Portfolio KITE Stock Details KITE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-10,000	Closed	-$1.04M	–	2240
2017 Q2	$1.04M	Buy	+10,000	New	+$816K	﹤0.01%	1183
2017 Q1	–	Sell	-30,000	Closed	-$1.38M	–	2234
2016 Q4	$1.38M	Buy	+30,000	New	+$1.47M	﹤0.01%	1023

Other funds holding KITE

Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

WCM

Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCSAM

Tyrus Capital S.A.M. Monaco $10.5M AUM 4.88% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Federated Hermes's KITE Position: Q3 2017 in Review

Federated Hermes sold out of Kite Pharma, Inc. (KITE) in Q3 2017, closing a stake of 24,460 shares — an estimated $2.54M sold.

Federated Hermes first reported a position in KITE in Q3 2014 and held it in 9 quarters. The position peaked at $2.54M in Q2 2017. 244 funds tracked by Wall St. Rank hold KITE as of Q3 2017.

Federated Hermes reported no remaining Kite Pharma, Inc. position as of Q3 2017 after selling out during the quarter.
Federated Hermes sold 24,460 Kite Pharma, Inc. shares in Q3 2017, an estimated $2.54M.
Federated Hermes first reported a position in Kite Pharma, Inc. in Q3 2014 and held it in 9 quarters.
Federated Hermes's Kite Pharma, Inc. position peaked at $2.54M in Q2 2017.
244 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q3 2017.

Based on Federated Hermes's 13F filing for Q3 2017, filed 13 Nov 2017.